Literature DB >> 24011291

HCC patients suffer less from geographic differences in organ availability.

C Schuetz1, N Dong, E Smoot, N Elias, D A Schoenfeld, J F Markmann, H Yeh.   

Abstract

It has been suggested that the number of exception model for end-stage liver disease (MELD) points for hepatocellular carcinoma (HCC) overestimates mortality risk. Average MELD at transplant, a measure of organ availability, correlates with mortality on an intent-to-treat basis and varies by donation service area (DSA). We analyzed Scientific Registry of Transplant Recipients data from 2005 to 2010, comparing transplant and death parameters for patients transplanted with HCC exception points to patients without HCC diagnosis (non-HCC), to determine whether the two groups were impacted differentially by DSA organ availability. HCC candidates are transplanted at higher rates than non-HCC candidates and are less likely to die on the waitlist. Overall risk of death trends downward by 1% per MELD point (p = 0.65) for HCC, but increases by 7% for non-HCC patients (p < 0.0001). The difference in the change of mortality with MELD is statistically significant between HCC and non-HCC candidates p < 0.0001. Posttransplant risk of death trends downward by 2% per MELD point (p = 0.28) for HCC patients, but increases by 3% per MELD point in non-HCC patients (p = 0.027), with the difference being statistically significant with p < 0.005. In summary, increasing wait time impacts HCC candidates less than non-HCC candidates and under increased competition for donor organs, HCC candidates' advantage increases. © Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  Hepatocellular carcinoma; MELD score; donation service area; liver transplantation; organ allocation

Mesh:

Year:  2013        PMID: 24011291      PMCID: PMC3833452          DOI: 10.1111/ajt.12441

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  26 in total

1.  Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy.

Authors:  Alessandro Cucchetti; Matteo Cescon; Eleonora Bigonzi; Fabio Piscaglia; Rita Golfieri; Giorgio Ercolani; Maria Cristina Morelli; Matteo Ravaioli; Antonio Daniele Pinna
Journal:  Liver Transpl       Date:  2011-11       Impact factor: 5.799

2.  Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.

Authors:  David Goldberg; Benjamin French; Peter Abt; Sandy Feng; Andrew M Cameron
Journal:  Liver Transpl       Date:  2012-04       Impact factor: 5.799

3.  Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system.

Authors:  K Washburn; E Edwards; A Harper; R Freeman
Journal:  Am J Transplant       Date:  2010-05-10       Impact factor: 8.086

4.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

Review 5.  The model for end-stage liver disease (MELD).

Authors:  Patrick S Kamath; W Ray Kim
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

6.  Poorer survival in patients whose explanted hepatocellular carcinoma (HCC) exceeds Milan or UCSF Criteria. An analysis of liver transplantation in HCC in Australia and New Zealand.

Authors:  John W C Chen; Lilian Kow; Deborah J Verran; John L McCall; Stephen Munn; Glenda A Balderson; Jonathan W Fawcett; Paul J Gow; Robert M Jones; Gary P Jeffrey; Anthony K House; Simone I Strasser
Journal:  HPB (Oxford)       Date:  2009-02       Impact factor: 3.647

7.  Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.

Authors:  John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

8.  Following the organ supply: assessing the benefit of inter-DSA travel in liver transplantation.

Authors:  Nino Dzebisashvili; Allan B Massie; Krista L Lentine; Mark A Schnitzler; Dorry Segev; Janet Tuttle-Newhall; Sommer Gentry; Richard Freeman; David A Axelrod
Journal:  Transplantation       Date:  2013-01-27       Impact factor: 4.939

9.  Liver transplantation for hepatocellular carcinoma: the MELD impact.

Authors:  Pratima Sharma; Vijayan Balan; Jose L Hernandez; Ann M Harper; Erick B Edwards; Hector Rodriguez-Luna; Thomas Byrne; Hugo E Vargas; David Mulligan; Jorge Rakela; Russell H Wiesner
Journal:  Liver Transpl       Date:  2004-01       Impact factor: 5.799

10.  Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease.

Authors:  Adnan Said; John Williams; Jeremy Holden; Patrick Remington; Ronald Gangnon; Alexandru Musat; Michael R Lucey
Journal:  J Hepatol       Date:  2004-06       Impact factor: 25.083

View more
  6 in total

1.  Impact of geography on organ allocation: Beyond the distance to the transplantation center.

Authors:  Rony Ghaoui; Jane Garb; Fredric Gordon; Elizabeth Pomfret
Journal:  World J Hepatol       Date:  2015-07-08

Review 2.  Model for end-stage liver disease score and MELD exceptions: 15 years later.

Authors:  Sumeet K Asrani; Patrick S Kamath
Journal:  Hepatol Int       Date:  2015-05-28       Impact factor: 6.047

3.  Patient-reported outcomes in liver transplant recipients with hepatocellular carcinoma.

Authors:  Clark D Kensinger; Irene D Feurer; Heather W O'Dell; David C LaNeve; Lindsey Simmons; C Wright Pinson; Derek E Moore
Journal:  Clin Transplant       Date:  2016-07-18       Impact factor: 2.863

4.  Patterns and Outcomes Associated with Patient Migration for Liver Transplantation in the United States.

Authors:  Kristopher P Croome; David D Lee; Justin M Burns; Dana K Perry; Andrew P Keaveny; C Burcin Taner
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

Review 5.  Management of Hepatocellular Carcinoma: Current Status and Future Directions.

Authors:  Jennifer S Au; Catherine T Frenette
Journal:  Gut Liver       Date:  2015-07       Impact factor: 4.519

6.  T2 Hepatocellular Carcinoma Exception Policies That Prolong Waiting Time Improve the Use of Evidence-based Treatment Practices.

Authors:  Claire Durkin; David E Kaplan; Therese Bittermann
Journal:  Transplant Direct       Date:  2020-08-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.